PREDILIFE: Predilife extends its network of partner insurance brokers: Roederer integrates Multi-pathology Prevention Reports into its health offer – 2022-11-16 at 18:00

Villejuif, France, November 16, 2022, 6 p.m. – PREDILIFE (Euronext Growth: ALPRE FR0010169920), a specialist in innovative pathology risk prediction solutions for personalized medicine, is pleased to announce a partnership with Roederer, the first independent generalist broker in the Great East. With this new signature, PREDILIFE brings to three the number of insurance brokers including the PREDILIFE offer in its catalog.

Thirteenth generalist broker in France and leading insurance broker in the Grand Est region, the Roederer group has 300,000 protected persons in France and more than 10,000 corporate clients. Fully involved in the prevention of serious illnesses, Roederer stands out for the effective and innovative solutions it offers to its members. It is in this context that the group decided to integrate multi-pathology assessments into its offer. Thus, the Roederer sales network will now offer all of its client companies the solution developed by PREDILIFE.

“We thank Roederer for his trust. A century-old broker, the Group has a long-term vision for its development and that of its clients. Roederer’s DNA matches ours and we can expect many fruits from this alliance.”

concludes Stéphane Ragusa, CEO and Founder of PREDILIFE.

About Roederer

Founded in 1893 in Strasbourg, the Roederer Group is the 13


generalist broker in France and the 1


insurance broker in the Grand Est region. We are delegated management of more than 20 insurance companies, mutuals and provident institutions. As an insurance broker, the Roederer Group puts its extensive experience in business insurance brokerage at your disposal and offers you solutions tailored to your needs.

About Predilife

PREDILIFE is a pioneering company in the design and development of predictive tests that can allow each person to define their risk profile for the occurrence of serious illnesses. It uses artificial intelligence methods applied to clinical medical data, genetics, imaging… PREDILIFE markets Mammorisk in Europe


a breast cancer risk prediction test and a multi-pathology prediction test.

For more information:


PREDILIFE Investor Relations

Stephane Ragusa

Chairman and CEO

[email protected]

CAPVALUE Press Relations

01 80 81 50 00

[email protected]

This post has the “🔒 Actusnews SECURITY MASTER” service.



– To check this key:

Regulated information:

Inside information:

– Other press releases

Full and original press release in PDF format:

© Copyright Actusnews Wire

Receive the company’s next press releases free of charge by email by subscribing to

Source link -86